New York, NY November 16, 2016 Dr. Yang joins Aegis Capital as part of the firm’s effort to build and refine its Equity Research Platform. Dr. Yang holds a Ph.D. in Chemistry from the University of California Los Angeles and a Bachelor of Science in Physics from Peking University, China; as well as an MBA from Georgia State University. Prior to joining Aegis Capital, she was a Managing Director covering Biotech/Specialty Pharmaceuticals at Brean Capital, R.F. Lafferty, WallachBeth Capital, Auriga USA and Capstone Investments. Prior to her roles in equity research, Dr. Yang spent 14 years in the pharmaceutical/biotech industry performing various functions, including R&D, marketing/sales, project management, business development/M&A and business analytics. Dr. Yang’s industry experience spans companies such as Becton Dickinson, Solvay Pharmaceuticals, Kimberly Clark and SpectRx. Dr. Yang holds multiple US patents and has had numerous articles published.

Robert Eide Aegis’ CEO Commented: “We are pleased to welcome Dr. Yang to our Aegis family as she possesses a wealth of knowledge in the healthcare-life sciences space. Dr. Yang will be a valued asset to the firm as part of our Equity Research group.”

Phil Michals Aegis’ Head of Business Development Commented: “We are pleased Dr. Yang has chosen Aegis Capital in order to represent our equity research efforts. Her leadership will be instrumental in expanding and enhancing our healthcare franchise.”

About Aegis- Aegis Capital has been in business for over 30 years and maintains a conflict free service platform catering to the needs of private clients, institutions and corporations. Aegis Capital Corp. was founded in 1984 by, the current CEO and Chairman. Aegis origins were based on servicing the specific needs of its customer base. Today, we have become a premiere full-service investment banking firm with 25 locations and employees stretching from Portland, Oregon to Rochester, NY. We have clients in all 50 states and overseas. Aegis has been able to bring quality service through its clearing relationships with RBC and APEX.

For more information, contact:

Business Development

Phil Michals-800-380-4241

pmichals@aegiscapcorp.com